Document:

Careview Communications, Inc. 8-K

Exhibit
10.38

 

THE
SECURITIES REPRESENTED HEREBY MAY NOT BE TRANSFERRED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO
THE SECURITIES ACT OF 1933, AS AMENDED, (II) SUCH SECURITIES MAY BE SOLD WITHOUT RESTRICTION PURSUANT TO RULE 144, OR (III) THE
COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH TRANSFER MAY LAWFULLY BE MADE WITHOUT REGISTRATION
UNDER THE SECURITIES ACT OF 1933 OR QUALIFICATION UNDER APPLICABLE STATE SECURITIES LAWS.

 

SUBJECT
TO THE PROVISIONS OF SECTION 15 HEREOF, THIS WARRANT SHALL BE VOID AFTER 5:00 P.M. EASTERN TIME ON MARCH 8, 2032 (THE “EXPIRATION
DATE”).

 

No.
G-[__]

 

CareView
Communications, Inc.

 

WARRANT
TO PURCHASE [                 ] SHARES OF

 

COMMON
STOCK, PAR VALUE $0.001 PER SHARE

 

For
VALUE RECEIVED, [_________________________] (“Warrantholder”), is entitled to purchase, subject to the provisions
of this Warrant, from CareView Communications, Inc., a Nevada corporation (“Company”), from and after March
8, 2022 (the “Issue Date”) and at any time not later than 5:00 P.M., Eastern time, on the Expiration Date (as
defined above), at an exercise price per share equal to $0.09 (the exercise price in effect being herein called the “Warrant
Price”), [________] shares (“Warrant Shares”) of the Company’s Common Stock, par value $0.001
per share (“Common Stock”). The number of Warrant Shares purchasable upon exercise of this Warrant and the
Warrant Price shall be subject to adjustment from time to time as described herein.

 

Section
1.     Registration. The Company shall maintain books for the transfer and registration of the
Warrant. Upon the initial issuance of this Warrant, the Company shall issue and register the Warrant in the name of the Warrantholder.

 

Section
2.     Transfers. As provided herein, this Warrant may be transferred only pursuant to a registration
statement filed under the Securities Act of 1933, as amended (the “Securities Act”), or an exemption from such
registration. Subject to such restrictions, the Company shall transfer this Warrant from time to time upon the books to be maintained
by the Company for that purpose, upon surrender hereof for transfer, properly endorsed or accompanied by appropriate instructions
for transfer and such other documents as may be reasonably required by the Company, including, if required by the Company, an
opinion of its counsel to the effect that such transfer is exempt from the registration requirements of the Securities Act, to
establish that such transfer is being made in accordance with the terms hereof, and a new Warrant shall be issued to the transferee
and the surrendered Warrant shall be canceled by the Company.

 

     

     

    

 

Section
3.     Exercise of Warrant. Subject to the provisions hereof, the Warrantholder may exercise this
Warrant, in whole or in part, at any time from and after the Issue Date and prior to its expiration upon surrender of the Warrant,
together with delivery of a duly executed Warrant exercise form, in the form attached hereto as Appendix A (the “Exercise
Agreement”) and payment by cash, certified check or wire transfer of funds (or, in certain circumstances, by cashless
exercise as provided below) of the aggregate Warrant Price for that number of Warrant Shares then being purchased, to the Company
during normal business hours on any business day at the Company’s principal executive offices or such other office or agency
of the Company as it may designate by notice to the Warrantholder (such date, the “Exercise Date”). The Warrant
Shares so purchased shall be deemed to be issued to the Warrantholder or the Warrantholder’s designee, as the record owner
of such shares, as of the close of business on the date on which this Warrant shall have been surrendered (or the date evidence
of loss, theft or destruction thereof and security or indemnity satisfactory to the Company has been provided to the Company),
the Warrant Price shall have been paid and the completed Exercise Agreement shall have been delivered. Execution and delivery
of the Exercise Agreement with respect to less than all of the Warrant Shares shall have the same effect as cancellation of the
original Warrant and issuance of a new Warrant evidencing the right to purchase the remaining number of Warrant Shares. On or
before the first (1st) business day following the Exercise Date, the Company shall transmit by facsimile an acknowledgment
of confirmation of receipt of the Exercise Agreement (or Net Issue Election Notice, if applicable, pursuant to Section 18) to
the Warrantholder and the Company’s transfer agent (the “Transfer Agent”).  On or before the third
(3rd) business day following the Exercise Date (the “Share Delivery Date”), the Company shall (A) provided
that the Transfer Agent is participating in The Depository Trust Company (“DTC”) Fast Automated Securities
Transfer Program, upon the request of the Warrantholder, credit such aggregate number of Warrant Shares to which the Warrantholder
is entitled pursuant to such exercise to the Warrantholder’s or its designee’s balance account with DTC through its
Deposit Withdrawal At Custodian system, or (B) if the Transfer Agent is not participating in the DTC Fast Automated Securities
Transfer Program, issue and deliver by overnight courier to the address as specified in the Exercise Agreement or Net Issue Election
Notice, a certificate, registered in the Company’s share register in the name of the Warrantholder or its designee, for
the number of shares of Common Stock to which the Warrantholder is entitled pursuant to such exercise. The Company shall be responsible
for all fees and expenses of the Transfer Agent and all fees and expenses with respect to the issuance of Warrant Shares via DTC,
if any.  Any certificates so delivered shall be in such denominations as may be requested by the Warrantholder and shall
be registered in the name of the Warrantholder or such other name as shall be designated by the Warrantholder, as specified in
the Exercise Agreement or Net Issue Election Notice, if applicable. If this Warrant shall have been exercised only in part, then,
unless this Warrant has expired, the Company shall, at its expense, at the time of delivery of such certificates (or of crediting
the Warrantholder’s balance account with DTC), deliver to the Warrantholder a new Warrant representing the right to purchase
the number of shares with respect to which this Warrant shall not then have been exercised. As used herein, “business
day” means a day, other than a Saturday or Sunday, on which banks in New York City are open for the general transaction
of business.

 

If
(1) the Company shall fail for any reason or no reason to issue to the Warrantholder within three (3) business days (such third
business day, a “Warrant Share Delivery Date”) after the Exercise Date, in compliance with the terms of this
Section 3, a certificate for the number of Warrant Shares to which the Warrantholder is entitled and register such shares on the
Company’s share register or to credit the Warrantholder’s balance account at DTC for such number of Warrant Shares
to which the Warrantholder is entitled upon the exercise of this Warrant, and (2) on or after the Warrant Share Delivery Date,
the Warrantholder, or any third party on behalf of the Warrantholder or for the Warrantholder’s account, purchases (in an
open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Warrantholder of shares
issuable upon exercise that the Warrantholder anticipated receiving from the Company (a “Buy-In”), then the
Company shall pay in cash to the Warrantholder (for costs incurred either directly by such Warrantholder or on behalf of a third
party) the amount by which the total purchase price paid for Common Stock as a result of the Buy-In (including brokerage commissions,
if any) exceeds the proceeds received by such Warrantholder as a result of the sale to which such Buy-In relates. The Warrantholder
shall provide the Company written notice indicating the amounts payable to the Warrantholder in respect of the Buy-In.

 

    2 

     

    

 

Section
4.     Compliance with the Securities Act. The Company may cause the legend set forth on the first
page of this Warrant to be set forth on each Warrant, and a similar legend on any security issued or issuable upon exercise of
this Warrant, unless counsel for the Company is of the opinion as to any such security that such legend is unnecessary.

 

Section
5.     Payment of Taxes. The Company will pay any documentary stamp taxes attributable to the
initial issuance of Warrant Shares issuable upon the exercise of this Warrant; provided, however, that the Company shall not be
required to pay any tax or taxes which may be payable in respect of any transfer involved in the issuance or delivery of any certificates
for Warrant Shares in a name other than that of the Warrantholder in respect of which such shares are issued, and in such case,
the Company shall not be required to issue or deliver any certificate for Warrant Shares or any Warrant until the person requesting
the same has paid to the Company the amount of such tax or has established to the Company’s reasonable satisfaction that
such tax has been paid. The Warrantholder shall be responsible for income taxes due under federal, state or other law, if any
such tax is due.

 

Section
6.     Mutilated or Missing Warrants. In case this Warrant shall be mutilated, lost, stolen, or
destroyed, the Company shall issue in exchange and substitution of and upon surrender and cancellation of the mutilated Warrant,
or in lieu of and substitution for the Warrant lost, stolen or destroyed, a new Warrant of like tenor and for the purchase of
a like number of Warrant Shares, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft
or destruction of the Warrant, and with respect to a lost, stolen or destroyed Warrant, reasonable indemnity or bond with respect
thereto, if requested by the Company.

 

Section
7.     Reservation of Common Stock. The Company hereby represents and warrants that there have
been reserved, and the Company shall at all applicable times keep reserved until issued (if necessary) as contemplated by this
Section 7, out of the authorized and unissued shares of Common Stock, sufficient shares to provide for the exercise of the rights
of purchase represented by this Warrant. The Company agrees that all Warrant Shares issued upon due exercise of this Warrant shall
be, at the time of delivery of the certificates for such Warrant Shares, duly authorized, validly issued, fully paid and non-assessable
shares of Common Stock of the Company.

 

    3 

     

    

 

Section
8.     Adjustments. Subject and pursuant to the provisions of this Section 8, the Warrant Price
and number of Warrant Shares subject to this Warrant shall be subject to adjustment from time to time as set forth hereinafter.

 

(a)     If
the Company shall, at any time or from time to time while this Warrant is outstanding, pay a dividend or make a distribution on
its Common Stock in shares of Common Stock, subdivide its outstanding shares of Common Stock into a greater number of shares or
combine its outstanding shares of Common Stock into a smaller number of shares or issue by reclassification of its outstanding
shares of Common Stock any shares of its capital stock (including any such reclassification in connection with a consolidation
or merger in which the Company is the continuing corporation), then (i) the Warrant Price in effect immediately prior to the date
on which such change shall become effective shall be adjusted by multiplying such Warrant Price by a fraction, the numerator of
which shall be the number of shares of Common Stock outstanding immediately prior to such change and the denominator of which
shall be the number of shares of Common Stock outstanding immediately after giving effect to such change and (ii) the number of
Warrant Shares purchasable upon exercise of this Warrant shall be adjusted by multiplying the number of Warrant Shares purchasable
upon exercise of this Warrant immediately prior to the date on which such change shall become effective by a fraction, the numerator
of which is shall be the Warrant Price in effect immediately prior to the date on which such change shall become effective and
the denominator of which shall be the Warrant Price in effect immediately after giving effect to such change, calculated in accordance
with clause (i) above. Such adjustments shall be made successively whenever any event listed above shall occur.

 

(b)     If
any capital reorganization, reclassification of the capital stock of the Company, consolidation or merger of the Company with
another corporation in which the Company is not the survivor, or sale, transfer or other disposition of all or substantially all
of the Company’s assets to another corporation shall be effected, then, as a condition of such reorganization, reclassification,
consolidation, merger, sale, transfer or other disposition, lawful and adequate provision shall be made whereby each Warrantholder
shall thereafter have the right to purchase and receive upon the basis and upon the terms and conditions herein specified and
in lieu of the Warrant Shares immediately theretofore issuable upon exercise of this Warrant, such shares of stock, securities
or assets as would have been issuable or payable with respect to or in exchange for a number of Warrant Shares equal to the number
of Warrant Shares immediately theretofore issuable upon exercise of this Warrant, had such reorganization, reclassification, consolidation,
merger, sale, transfer or other disposition not taken place, and in any such case appropriate provision shall be made with respect
to the rights and interests of each Warrantholder to the end that the provisions hereof (including, without limitation, provision
for adjustment of the Warrant Price) shall thereafter be applicable, as nearly equivalent as may be practicable in relation to
any shares of stock, securities or assets thereafter deliverable upon the exercise hereof. The Company shall not effect any such
consolidation, merger, sale, transfer or other disposition unless prior to or simultaneously with the consummation thereof the
successor corporation (if other than the Company) resulting from such consolidation or merger, or the corporation purchasing or
otherwise acquiring such assets or other appropriate corporation or entity shall assume the obligation to deliver to the Warrantholder,
at the last address of the Warrantholder appearing on the books of the Company, such shares of stock, securities or assets as,
in accordance with the foregoing provisions, the Warrantholder may be entitled to purchase, and the other obligations under this
Warrant. The provisions of this paragraph (b) shall similarly apply to successive reorganizations, reclassifications, consolidations,
mergers, sales, transfers or other dispositions.

 

    4 

     

    

 

(c)     In
case the Company shall fix a payment date for the making of a distribution to all holders of Common Stock (including any such
distribution made in connection with a consolidation or merger in which the Company is the continuing corporation) of evidences
of indebtedness or assets (other than cash dividends or cash distributions payable out of consolidated earnings or earned surplus
or dividends or distributions referred to in Section 8(a)), or subscription rights or warrants, the Warrant Price to be in effect
after such payment date shall be determined by multiplying the Warrant Price in effect immediately prior to such payment date
by a fraction, the numerator of which shall be the total number of shares of Common Stock outstanding multiplied by the Market
Price (as defined below) per share of Common Stock immediately prior to such payment date, less the fair market value (as determined
by the Company’s Board of Directors in good faith) of said assets or evidences of indebtedness so distributed, or of such
subscription rights or warrants, and the denominator of which shall be the total number of shares of Common Stock outstanding
multiplied by such Market Price per share of Common Stock immediately prior to such payment date. “Market Price”
as of a particular date (the “Valuation Date”) shall mean the following: (a) if the Common Stock is then listed
on The Nasdaq Stock Market or any other national stock exchange, the closing sale price of one share of Common Stock on such exchange
on the last trading day prior to the Valuation Date; (b) if the Common Stock is then quoted on a tiered marketplace of the OTC
Markets Group Inc. (the “Bulletin Board”) or a similar quotation system or association, the closing sale price
of one share of Common Stock on the Bulletin Board or such other quotation system or association on the last trading day prior
to the Valuation Date or, if no such closing sale price is available, the average of the high bid and the low asked price quoted
thereon on the last trading day prior to the Valuation Date; or (c) if the Common Stock is not then listed on a national stock
exchange or quoted on the Bulletin Board or such other quotation system or association, the fair market value of one share of
Common Stock as of the Valuation Date, as determined in good faith by the Board of Directors of the Company and the Warrantholder.
If the Common Stock is not then listed on a national securities exchange, the Bulletin Board or such other quotation system or
association, the Board of Directors of the Company shall respond promptly, in writing, to an inquiry by the Warrantholder prior
to the exercise hereunder as to the fair market value of a share of Common Stock as determined by the Board of Directors of the
Company. In the event that the Board of Directors of the Company and the Warrantholder are unable to agree upon the fair market
value in respect of subpart (c) of this paragraph, the Company and the Warrantholder shall jointly select an appraiser, who is
experienced in such matters. The decision of such appraiser shall be final and conclusive, and the cost of such appraiser shall
be borne equally by the Company and the Warrantholder. Such adjustment shall be made successively whenever such a payment date
is fixed.

 

(d)     An
adjustment to the Warrant Price shall become effective immediately after the payment date in the case of each dividend or distribution
and immediately after the effective date of each other event which requires an adjustment.

 

(e)     In
the event that, as a result of an adjustment made pursuant to this Section 8, the Warrantholder shall become entitled to receive
any shares of capital stock of the Company other than shares of Common Stock, the number of such other shares so receivable upon
exercise of this Warrant shall be subject thereafter to adjustment from time to time in a manner and on terms as nearly equivalent
as practicable to the provisions with respect to the Warrant Shares contained in this Warrant.

 

    5 

     

    

 

(f)     To
the extent permitted by applicable law and the listing requirements of any stock market or exchange on which the Common Stock
is then listed, the Company from time to time may decrease the Warrant Price by any amount for any period of time if (i) the period
is at least twenty (20) days, (ii) the decrease is irrevocable during the period, and (iii) the Board shall have made a determination
that such decrease would be in the best interests of the Company, which determination shall be conclusive. Whenever the Warrant
Price is decreased pursuant to the preceding sentence, the Company shall provide written notice thereof to the Warrantholder at
least five (5) days prior to the date the decreased Warrant Price takes effect, and such notice shall state the decreased Warrant
Price and the period during which it will be in effect.

 

Section
9.     Fractional Interest. The Company shall not be required to issue fractions of Warrant Shares
upon the exercise of this Warrant. If any fractional share of Common Stock would, except for the provisions of the first sentence
of this Section 9, be deliverable upon such exercise, the Company, in lieu of delivering such fractional share, shall pay to the
exercising Warrantholder an amount in cash equal to the Market Price of such fractional share of Common Stock on the date of exercise.

 

Section
10.   Registration Rights. The Warrant Shares deliverable upon exercise of this Warrant shall be deemed
“Registrable Securities” under, and the Warrantholder shall have the registration rights with respect to such shares
under and as set forth in, the Registration Rights Agreement dated as of April 21, 2011 between and among the Company, the initial
Warrantholder and the other parties thereto from time to time (as amended from time to time, the “Registration Rights
Agreement”), on a pari passu basis with the rights of the holders of the Registrable Securities who are parties
thereto.

 

Section
11.   Benefits. Nothing in this Warrant shall be construed to give any person, firm or corporation (other
than the Company and the Warrantholder) any legal or equitable right, remedy or claim, it being agreed that this Warrant shall
be for the sole and exclusive benefit of the Company and the Warrantholder.

 

Section
12.   Notices to Warrantholder. Upon the happening of any event requiring an adjustment of the Warrant Price,
the Company shall promptly give written notice thereof to the Warrantholder at the address appearing in the records of the Company,
stating the adjusted Warrant Price and the adjusted number of Warrant Shares resulting from such event and setting forth in reasonable
detail the method of calculation and the facts upon which such calculation is based. Failure to give such notice to the Warrantholder
or any defect therein shall not affect the legality or validity of the subject adjustment.

 

Section
13.   Identity of Transfer Agent. The Transfer Agent for the Common Stock is Holladay Stock Transfer, Inc.
Upon the appointment of any subsequent transfer agent for the Common Stock or other shares of the Company’s capital stock
issuable upon the exercise of the rights of purchase represented by the Warrant, the Company will mail to the Warrantholder a
statement setting forth the name and address of such transfer agent.

 

    6 

     

    

 

Section
14.   Notices. Unless otherwise provided, any notice required or permitted under this Warrant shall be given
in writing and shall be deemed effectively given as hereinafter described (i) if given by personal delivery, then such notice
shall be deemed given upon such delivery, (ii) if given by telex or facsimile, then such notice shall be deemed given upon receipt
of confirmation of complete transmittal, (iii) if given by mail, then such notice shall be deemed given upon the earlier of (A)
receipt of such notice by the recipient or (B) three days after such notice is deposited in first class mail, postage prepaid,
and (iv) if given by an internationally recognized overnight air courier, then such notice shall be deemed given one business
day after delivery to such carrier. All notices shall be addressed as follows: if to the Warrantholder, at its address as set
forth in the Company’s books and records and, if to the Company, at the address as follows, or at such other address as
the Warrantholder or the Company may designate by ten days’ advance written notice to the other:

 

If
to the Company:

 

CareView
Communications, Inc.

405 State Highway 121

Suite B-240 

Lewisville,
TX 75067

Attention: Chief Executive Officer

Fax: (972) 403-7659

 

With
a copy to:

 

Law
Offices of Carl A. Generes 

4358
Shady Bend Drive 

Dallas,
Texas 75244-7447 

Attn:
Carl A. Generes 

Fax:
(972) 715-5700

 

Section
15.   Extension of Expiration Date. If the Company fails to cause any Registration Statement covering Registrable
Securities (each as defined in the Registration Rights Agreement) to be declared effective prior to the applicable dates set forth
therein, or if any of the events specified in Section 3(b) of the Registration Rights Agreement occurs, and the Blackout Period
(as defined in the Registration Rights Agreement) (whether alone, or in combination with any other Blackout Period) continues
for more than 60 days in any 12 month period, or for more than a total of 90 days, then the Expiration Date of this Warrant shall
be extended one day for each day beyond the 60-day or 90-day limits, as the case may be, that the Blackout Period continues.

 

Section
16.    Successors. All the covenants and provisions hereof by or for the benefit of the Warrantholder shall
bind and inure to the benefit of its respective successors and permitted assigns hereunder.

 

    7 

     

    

 

Section
17.   Governing Law; Consent to Jurisdiction; Waiver of Jury Trial. This Warrant shall be governed by, and
construed in accordance with, the internal laws of the State of Delaware, without reference to the choice of law provisions thereof.
The Company and, by accepting this Warrant, the Warrantholder, each irrevocably submits to the exclusive jurisdiction of the courts
of the State of Delaware and the United States District Court for the District of Delaware for the purpose of any suit, action,
proceeding or judgment relating to or arising out of this Warrant and the transactions contemplated hereby. Service of process
in connection with any such suit, action or proceeding may be served on each party hereto anywhere in the world by the same methods
as are specified for the giving of notices under this Warrant. The Company and, by accepting this Warrant, the Warrantholder,
each irrevocably consents to the jurisdiction of any such court in any such suit, action or proceeding and to the laying of venue
in such court. The Company and, by accepting this Warrant, the Warrantholder, each irrevocably waives any objection to the laying
of venue of any such suit, action or proceeding brought in such courts and irrevocably waives any claim that any such suit, action
or proceeding brought in any such court has been brought in an inconvenient forum. EACH OF THE COMPANY AND, BY ITS ACCEPTANCE
HEREOF, THE WARRANTHOLDER HEREBY WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS WARRANT AND
REPRESENTS THAT COUNSEL HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER.

 

Section
18.   Cashless Exercise. Notwithstanding any other provision contained herein to the contrary, the Warrantholder
may elect to receive, without the payment by the Warrantholder of the aggregate Warrant Price in respect of the shares of Common
Stock to be acquired, shares of Common Stock of equal value to the value of this Warrant, or any specified portion hereof, by
the surrender of this Warrant (or such portion of this Warrant being so exercised) together with a Net Issue Election Notice,
in the form annexed hereto as Appendix B (the “Net Issue Election Notice”), duly executed, to the Company.
Thereupon, the Company shall issue to the Warrantholder such number of fully paid, validly issued and nonassessable shares of
Common Stock as is computed using the following formula:

 

	X
    = Y (A - B)
	        A

 

where

 

X
=       the number of shares of Common Stock to which the Warrantholder is entitled upon such
cashless exercise;

 

Y
=       the total number of shares of Common Stock covered by this Warrant for which the Warrantholder
has surrendered purchase rights at such time for cashless exercise (including both shares to be issued to the Warrantholder and
shares as to which the purchase rights are to be canceled as payment therefor);

 

A
=       the “Market Price” of one share of Common Stock as at the date the net
issue election is made; and

 

B
=       the Warrant Price in effect under this Warrant at the time the net issue election is
made.

 

Section
19.   No Rights as Shareholder. Prior to the exercise of this Warrant, the Warrantholder shall not have or exercise any
rights as a shareholder of the Company by virtue of its ownership of this Warrant.

 

    8 

     

    

 

Section
20.   Amendment; Waiver; Termination. Any term of this Warrant may be amended or waived (including the adjustment
provisions included in Section 8 of this Warrant) only upon the written consent of the Company and the Warrantholder or its successors
and assigns.

 

Section
21.   Section Headings. The section headings in this Warrant are for the convenience of the Company and
the Warrantholder and in no way alter, modify, amend, limit or restrict the provisions hereof.

 

[Signature
Page Follows.]

 

    9 

     

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be duly executed, as of the 8th day of March, 2022.

 

	 	CAREVIEW COMMUNICATIONS, INC.
	 	 	 
	 	By:	                      
	 	Name: Steven G. Johnson
	 	Title: President

 

     

     

    

 

APPENDIX
A

CAREVIEW COMMUNICATIONS, INC.

WARRANT EXERCISE FORM

 

To
CareView Communications, Inc.:

 

The
undersigned hereby irrevocably elects to exercise the right of purchase represented by the within Warrant (“Warrant”)
for, and to purchase thereunder by the payment of the Warrant Price and surrender of the Warrant, _______________ shares of Common
Stock (“Warrant Shares”) provided for therein, and requests that certificates for the Warrant Shares be issued
as follows:

 

	Name
	 
	Address
	 
	 
	Federal Tax ID or Social Security No.

 

	and delivered by:	(   ) certified mail to the above address,
or

(   )
electronically (provide DWAC Instructions:___________________), or 

(   )
other (specify): __________________________________________.

 

and,
if the number of Warrant Shares shall not be all the Warrant Shares purchasable upon exercise of the Warrant, that a new Warrant
for the balance of the Warrant Shares purchasable upon exercise of this Warrant be registered in the name of the undersigned Warrantholder
or the undersigned’s Assignee as below indicated and delivered to the address stated below.

 

Dated:
___________________, ____

 

	 	Signature:	 

 

	Note:  The
    signature must correspond with the name of the Warrantholder as written on the first page of the Warrant in every particular,
    without alteration or enlargement or any change whatever, unless the Warrant has been assigned.	 	 
	 	 
	 	 
	 	Name (please print)
	 	 
	 	 
	 	 
	 	Address
	 	 
	 	Federal Identification or
	 	Social Security No.
	 	 
	 	Assignee:  
	 	 
	 	 

 

     

     

    

 

APPENDIX
B 

CAREVIEW
COMMUNICATIONS, INC. 

NET
ISSUE ELECTION NOTICE

 

To:
CareView Communications, Inc.

 

Date:[_________________________]

 

The
undersigned hereby elects under Section 18 of this Warrant to surrender the right to purchase [____________] shares of
Common Stock pursuant to this Warrant and hereby requests the issuance of [_____________] shares of Common Stock. The certificate(s)
for the shares issuable upon such net issue election shall be issued in the name of the undersigned or as otherwise indicated
below.

 

	Signature	 
	 	 
	 	 
	Name for Registration	 
	 	 
	 	 
	Mailing AddressCareview Communications, Inc. 8-K

Exhibit
10.39

 

CONSENT
AND AGREEMENT PURSUANT TO 

NOTE AND WARRANT PURCHASE AGREEMENT

 

This
CONSENT AND AGREEMENT PURSUANT TO NOTE AND WARRANT PURCHASE AGREEMENT,
dated as of March 8, 2022 (this “Consent Agreement”), is made by and among CAREVIEW COMMUNICATIONS, INC.,
a Nevada corporation (the “Company”), the HealthCor Parties (as defined below), and such additional Existing
Investors (as defined below) as, together with the HealthCor Parties (collectively, the “Majority Investors”),
are holders of at least a majority of the shares of Common Stock issued or issuable (on an as converted basis) upon conversion
of the Notes and Warrants.

 

WITNESSETH:

 

WHEREAS,
the Company, HealthCor Partners Fund, L.P. (“HealthCor Partners”), HealthCor Hybrid Offshore Master Fund, L.P.
(“HealthCor Hybrid” and, together with HealthCor Partners, the “HealthCor Parties”) and
certain additional investors that purchased additional Notes and additional Warrants on February 17, 2015 (the “2015
Investors”), additional Notes and additional Warrants on February 23, 2018 (the “February 2018 Investors”),
additional Notes on July 13, 2018 (the “July 2018 Investors”), additional Notes on May 15, 2019 (the “2019
Investor”) and additional Notes on February 6, 2020 (the “2020 Investor” and, together with the 2015
Investors, the February 2018 Investors, the July 2018 Investors, the 2019 Investor and the HealthCor Parties, the “Existing
Investors”) are parties to that certain Note and Warrant Purchase Agreement, dated as of April 21, 2011 (as amended
from time to time, including without limitation pursuant to that certain Note and Warrant Amendment Agreement dated December 30,
2011, that certain Second Amendment to Note and Warrant Purchase Agreement dated January 31, 2012, that certain Third Amendment
to Note and Warrant Purchase Agreement dated August 20, 2013, that certain Fourth Amendment to Note and Warrant Purchase Agreement
dated January 16, 2014, that certain Fifth Amendment to Note and Warrant Purchase Agreement dated December 15, 2014, that certain
Sixth Amendment to Note and Warrant Purchase Agreement dated March 31, 2015, that certain Seventh Amendment to Note and Warrant
Purchase Agreement dated June 26, 2015, that certain Eighth Amendment to Note and Warrant Purchase Agreement dated February 23,
2018, that certain Ninth Amendment to Note and Warrant Purchase Agreement dated July 10, 2018, that certain Tenth Amendment to
Note and Warrant Purchase Agreement dated July 13, 2018, that certain Eleventh Amendment to Note and Warrant Purchase Agreement
dated March 27, 2019, that certain Twelfth Amendment to Note and Warrant Purchase Agreement dated May 15, 2019 and that certain
Thirteenth Amendment to Note and Warrant Purchase Agreement dated February 6, 2020, the “Purchase Agreement”);

 

WHEREAS,
as contemplated by the Purchase Agreement, the Company issued and sold (a) $20,000,000 initial principal amount of Notes (the
“2011 Notes”) and Warrants to purchase 11,782,859 shares of Common Stock to the HealthCor Parties on April
21, 2011, (b) $5,000,000 initial principal amount of Supplemental Closing Notes (the “2012 Notes”) to the HealthCor
Parties on January 31, 2012, (c) $5,000,000 initial principal amount of 2014 Supplemental Closing Notes and 2014 Supplemental
Warrants to purchase 4,000,000 shares of Common Stock to the HealthCor Parties on January 16, 2014, (d) $6,000,000 initial principal
amount of Fifth Amendment Supplemental Closing Notes and Fifth Amendment Supplemental Warrants to purchase 3,692,308 shares of
Common Stock to HealthCor Partners and the 2015 Investors on February 17, 2015, (e) $2,050,000 initial principal amount of Eighth
Amendment Supplemental Notes and Eighth Amendment Supplemental Warrants to purchase 512,500 shares of Common Stock to the February
2018 Investors on February 23, 2018, (f) $1,000,000 initial principal amount of Tenth Amendment Supplemental Notes to the July
2018 Investors on July 13, 2018, (g) $50,000 initial principal amount of Twelfth Amendment Supplemental Notes to the 2019 Investor
on May 15, 2019 and (h) $100,000 initial principal amount of Thirteenth Amendment Supplemental Notes to the 2020 Investor on February
6, 2020;

 

     

     

    

 

WHEREAS,
pursuant to Section 7.9 of the Purchase Agreement and subject to the terms and conditions contained herein, the Majority Investors
desire to consent to the amendment of the 2011 Notes and 2012 Notes through the execution and delivery by the Company and the
HealthCor Parties of Allonge No. 4 to the 2011 Notes and Allonge No. 4 to the 2012 Notes, in the forms attached as Exhibit
A and Exhibit B hereto, respectively, for the purposes of (a) extending the maturity date of the 2011 Notes from April
20, 2022 to April 20, 2023 and (b) extending the maturity date of the 2012 Notes from April 20, 2022 to April 20, 2023 (such amendments
to the 2011 Notes and 2012 Notes together, the “HealthCor Note Extensions”); in each case retaining the existing
provision for the potential earlier repayment thereof subject to certain conditions, including the Company’s senior debt
being repaid in full, being first met; and

 

WHEREAS,
pursuant to Section 7.9 of the Purchase Agreement and subject to the terms and conditions contained herein, the Majority Investors
desire to (a) consent pursuant to Section 6.12 of the Purchase Agreement to the Company’s issuance of warrants in the form
attached as Exhibit C hereto for the purchase of an aggregate of 3,000,000 shares of Common Stock, with an exercise price
per share equal to $0.09 (subject to adjustment as described therein), to the HealthCor Parties in consideration of the HealthCor
Note Extensions (such warrants collectively, the “2022 HealthCor Warrants”) and (b) waive the Investors’
rights, if any, as set forth under Section 5.4 of the Purchase Agreement (the “Preemptive Rights”) with respect
to the issuance of the 2022 HealthCor Warrants, including without limitation any notice rights thereunder.

 

NOW,
THEREFORE, in consideration of the agreements hereinafter set forth, and for other good and valuable consideration, the receipt
and adequacy of which are hereby acknowledged, the parties hereto agree as follows:

 

1.             Definitions.
Capitalized terms used in this Consent Agreement but not defined in this Consent Agreement shall have the meanings ascribed to
them in the Purchase Agreement.

 

2.             Consent
to Amendment of 2011 Notes and 2012 Notes. The Majority Investors hereby consent, pursuant to Section 7.9 of the Purchase
Agreement, to the amendment of the 2011 Notes and 2012 Notes through the execution and delivery by the Company and the HealthCor
Parties of the HealthCor Note Extensions.

 

3.            Consent
to Issuance of 2022 HealthCor Warrants. The Majority Investors hereby consent, pursuant to Section 6.12 and Section 7.9 of
the Purchase Agreement, to the Company’s issuance of the 2022 HealthCor Warrants.

 

    2 

     

    

 

4.             Waiver
of Preemptive Rights. The Majority Investors hereby waive, pursuant to Section 7.9 of the Purchase Agreement, the Preemptive
Rights, if any, of the Investors as set forth under Section 5.4 of the Purchase Agreement with respect to the issuance of the
2022 HealthCor Warrants, including without limitation any notice rights thereunder.

 

5.            Registration
Rights. The Company, the HealthCor Parties and the Majority Investors (representing the holders of a majority of the “Registrable
Securities” as defined in the Registration Rights Agreement) hereby agree that the 2022 HealthCor Warrants shall be considered
“Warrants” for purposes of Section 1(n) of the Registration Rights Agreement and the shares issuable upon exercise
of the 2022 HealthCor Warrants shall be considered “Warrant Shares” and “Registrable Securities” for purposes
of Sections 1(o) and 1(i), respectively, of the Registration Rights Agreement.

 

		6.	Miscellaneous.

 

(a)        Ratification
and Confirmation. The Company acknowledges, agrees and confirms that the Purchase Agreement and each of the other Transaction
Documents, except as expressly set forth in this Consent Agreement, are and shall continue to be in full force and effect and
are hereby in all respects ratified and confirmed.

 

(b)        Expenses.
The Company will pay and bear full responsibility for the reasonable legal fees and other out-of-pocket costs and expenses of
the Investors attributable to the negotiation and consummation of the transactions contemplated hereby.

 

(c)        Governing
Law. All questions concerning the construction, interpretation and validity of this Consent Agreement shall be governed by
and construed and enforced in accordance with the domestic laws of the State of Delaware without giving effect to any choice or
conflict of law provision or rule (whether in the State of Delaware or any other jurisdiction) that would cause the application
of the laws of any jurisdiction other than the State of Delaware. In furtherance of the foregoing, the internal law of the State
of Delaware will control the interpretation and construction of this Consent Agreement, even if under such jurisdiction’s
choice of law or conflict of law analysis, the substantive law of some other jurisdiction would ordinarily or necessarily apply.

 

(d)        Construction.
The Company and the Investors acknowledge that the Company and its independent counsel and the Investors and their independent
counsel have jointly reviewed and drafted this document, and agree that any rule of construction and interpretation to the effect
that drafting ambiguities are to be resolved against the drafting party shall not be employed.

 

(e)        Counterparts;
Facsimile and Electronic Signatures. This Consent Agreement may be executed in any number of counterparts, and each such counterpart
hereof shall be deemed to be an original instrument, but all such counterparts together shall constitute but one agreement. Counterpart
signatures to this Consent Agreement delivered by facsimile or other electronic transmission shall be acceptable and binding.

 

    3 

     

    

 

(f)        Headings.
The section and paragraph headings contained in this Consent Agreement are for reference purposes only and shall not affect in
any way the meaning or interpretation of this Consent Agreement.

 

[Signature
Pages Follow]

 

    4 

     

    

 

IN
WITNESS WHEREOF, each of the undersigned has duly executed this Consent Agreement as of the date first written above.

 

	 	COMPANY:
	 	 	 
	 	CareView Communications, Inc.,
    a Nevada corporation
	 	 	 
	 	By:	/s/ Steven
    G. Johnson
	 	 	Name: Steven G. Johnson
	 	 	Title: President

 

[Signature
Page to Consent Agreement]

 

     

     

    

 

	 	MAJORITY INVESTORS:
	 	 	 
	 	HealthCor Partners Fund, L.P.
	 	By: HealthCor Partners Management
    L.P., as Manager
	 	By: HealthCor Partners Management,
    G.P., LLC, as General Partner
	 	 	 
	 	By:	/s/
    Jeffrey C. Lightcap
	 	Name: Jeffrey C. Lightcap
	 	Title: Senior Managing Director
	 	Address:	HealthCor Partners
	 	 	1325 Avenue of Americas, 27th Floor
	 	 	New York, NY 10019
	 	 	 
	 	HealthCor Hybrid Offshore Master
    Fund, L.P.
	 	By: HealthCor Hybrid Offshore G.P.,
    LLC, as General Partner
	 	 	 
	 	By:	/s/
    Laurie Hadick
	 	Name: Laurie Hadick
	 	Title: CCO
	 	Address:	HealthCor Partners
	 	 	1325 Avenue of Americas, 27th Floor
	 	 	New York, NY 10019
	 	 	 	 

[Signature
Page to Consent Agreement]

 

     

     

    

 

	 	MAJORITY INVESTORS:
	 	 
	 	/s/ Steven
    B. Epstein
	 	Steven B. Epstein
	 	 
	 	/s/ Dr.
    James R. Higgins
	 	Dr. James R. Higgins
	 	 
	 	/s/ Steven
    G. Johnson
	 	Steven G. Johnson
	 	 
	 	/s/
    Jeffrey C. Lightcap
	 	Jeffrey C. Lightcap
	 	 

[Signature
Page to Consent Agreement]

 

     

     

    

 

ACKNOWLEDGED
AND AGREED:

 

	CareView Communications, Inc.,
    a Texas corporation	 
	 	 	 
	By:	/s/ Steven
    G. Johnson	 
	Name:	 Steven G. Johnson	 
	Title:	President	 
	 	 	 
	CareView Operations, LLC	 
	 	 	 
	By:	/s/ Steven
    G. Johnson	 
	Name:	 Steven G. Johnson	 
	Title:	President	 

 

[Signature
Page to Consent Agreement]

 

     

     

    

 

Exhibit
A

 

Form
of Allonge No. 4 to the 2011 Notes

 

(Attached)

 

     

     

    

 

Exhibit
B

 

Form
of Allonge No. 4 to the 2012 Notes

 

(Attached)

 

     

     

    

 

Exhibit
C

 

Form
of 2022 HealthCor Warrants

 

(Attached)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}]]